Varlilumab

Drug Profile

Varlilumab

Alternative Names: CDX-1127

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celldex Therapeutics Inc
  • Developer Celldex Therapeutics Inc; Oncothyreon; University of California at San Francisco; University of Virginia
  • Class Antigens; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD27 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malignant melanoma; Solid tumours
  • Phase I/II Renal cell carcinoma
  • Phase I Glioma; Prostate cancer
  • No development reported Haematological malignancies
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Haematological-malignancies in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)
  • 18 Aug 2017 University Hospital Southampton NHS Foundation Trust and Cancer Research UK plans a phase II RiVa trial for Diffuse large B cell lymphoma, Follicular lymphoma, MALT lymphoma, Mantle cell lymphoma and Waldenstrom's macroglobulinaemia (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in United Kingdom in August 2017 (ISRCTN15025004) (EudraCT2017-000302-37)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top